Stockscreener 앱 받기
1.65
1.23%
0.02
전일 마감가:
$1.63
열려 있는:
$1.63
하루 거래량:
2.75M
Relative Volume:
1.28
시가총액:
$329.67M
수익:
$314.00K
순이익/손실:
$-40.23M
주가수익비율:
-5.8929
EPS:
-0.28
순현금흐름:
$-84.71M
1주 성능:
+18.71%
1개월 성능:
+16.20%
6개월 성능:
+2.48%
1년 성능:
-11.29%
1일 변동 폭
$1.63
$1.76
1주일 범위
$1.375
$1.76
52주 변동 폭
$1.03
$2.565
Atai Life Sciences N V Stock (ATAI) Company Profile
명칭
Atai Life Sciences N V
전화
49 89 2153 9035
주소
WALLSTRASSE 16, BERLIN
ATAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
1.65 | 277.72M | 314.00K | -40.23M | -84.71M | -0.28 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-03 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
| 2021-11-11 | 개시 | ROTH Capital | Buy |
| 2021-10-18 | 개시 | H.C. Wainwright | Buy |
| 2021-09-01 | 개시 | Jefferies | Buy |
| 2021-07-13 | 개시 | Berenberg | Buy |
| 2021-07-13 | 개시 | Canaccord Genuity | Buy |
| 2021-07-13 | 개시 | Cantor Fitzgerald | Buy |
| 2021-07-13 | 개시 | Citigroup | Buy |
| 2021-07-13 | 개시 | Cowen | Outperform |
| 2021-07-13 | 개시 | Credit Suisse | Outperform |
| 2021-07-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | 개시 | Aegis Capital | Buy |
모두보기
Atai Life Sciences N V 주식(ATAI)의 최신 뉴스
ATAI Explores Psychedelic Solutions for Veterans' Mental Health - GuruFocus
ATAI Explores Psychedelic Solutions for Veterans' Mental Health | ATAI Stock News - GuruFocus
Atai Life Sciences: Progress in Psychedelic Mental Health Treatments - TipRanks
Will Atai Get A New Lease Of Life? - RTTNews
Atai Life Sciences Reports First Quarter 2025 Financial Results - marketscreener.com
ATAI Reports Significant First Quarter Revenue Growth | ATAI Sto - GuruFocus
ATAI Sees Financial Boost with Cash Reserves Rise | ATAI Stock N - GuruFocus
ATAI Reports Significant First Quarter Revenue Growth | ATAI Stock News - GuruFocus
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates - The Manila Times
Certain Options of Atai Life Sciences N.V. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
ATAI Begins Phase 2 Study for Social Anxiety Treatment | ATAI St - GuruFocus
Atai Life Sciences Announces First Patient Dosed In Phase 2 Study Of Emp-01 For The Treatment Of Social Anxiety Disorder - marketscreener.com
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder - Yahoo
ATAI Life Sciences Repays Hercules Loan Early - TipRanks
Daily Market Movement: ATAI Life Sciences N.V (ATAI) Sees a -2.00 Decrease, Closing at 1.47 - DWinneX
ATAI Life Sciences N.V [ATAI] Records 50-Day SMA of $1.4948 - knoxdaily.com
ATAI Life Sciences N.V: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - investchronicle.com
Have you been able to find a good deal on ATAI Life Sciences N.V’s shares? - uspostnews.com
Atai Life Sciences N.V. Announces Executive Changes - marketscreener.com
ATAI Life Sciences N.V (ATAI)’s Market Momentum: Closing Strong at 1.51, Down -3.82 - DWinneX
An Analysis of ATAI Life Sciences N.V (ATAI)’s Potential Price Growth - knoxdaily.com
ATAI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
ATAI Life Sciences N.V [ATAI] stock for 65,560 USD was sold by Kirpekar Sahil - knoxdaily.com
How Will ATAI Life Sciences N.V (NASDAQ: ATAI) Perform In Months To Come? - Marketing Sentinel
Investing in ATAI Life Sciences N.V (ATAI) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
Atai Life Sciences: Pipeline And Regulatory Uncertainties Warrant Hold Rating - Seeking Alpha
Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine
At What Point In Time Would I Choose To Purchase ATAI Life Sciences N.V (NASDAQ: ATAI) Stock? - stocksregister.com
A stock that deserves closer examination: ATAI Life Sciences N.V (ATAI) - uspostnews.com
Psychedelic Drugs Market Future Business Opportunities - openPR.com
ATAI Life Sciences N.V (NASDAQ: ATAI) Is Currently -99.23 Percent Below Its 52-Week High, But It Still Offers Strong Upside Potential. – Marketing Sentinel - Marketing Sentinel
Investor’s Delight: ATAI Life Sciences N.V (ATAI) Closes Weak at 1.27, Down -3.05 - DWinneX
Berenberg starts atai Life Sciences coverage with Positive rating By Investing.com - Investing.com Australia
Berenberg starts atai Life Sciences coverage with Positive rating - Investing.com
ATAI Life Sciences N.V (ATAI) Volatility Hits 10.40% – Here’s What A Good Investor Should Do - Stocksregister
Is Atai Life Sciences (ATAI) the Best German Stock to Buy According to Hedge Funds? - Insider Monkey
Is it possible to buy ATAI Life Sciences N.V(ATAI) shares at a good price now? - uspostnews.com
How Are Things Looking For ATAI Life Sciences N.V (NASDAQ: ATAI) For The Short Term? - stocksregister.com
ATAI Life Sciences N.V (ATAI) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com
Insiders Make Huge Purchases of These 4 Biotech Stocks - 24/7 Wall St.
Atai Life Sciences chief scientific officer sells $17,767 in shares By Investing.com - Investing.com India
Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares By Investing.com - Investing.com South Africa
Atai life sciences CMO Craig James sells $15,610 in shares By Investing.com - Investing.com South Africa
Atai Life Sciences chief business officer sells $65,560 in stock By Investing.com - Investing.com South Africa
Atai Life Sciences chief business officer sells $65,560 in stock - Investing.com India
Atai Life Sciences CFO sells shares worth $45,285 - Investing.com India
Atai life sciences CMO Craig James sells $15,610 in shares - Investing.com India
Atai Life Sciences chief scientific officer sells $17,767 in shares - Investing.com
Atai Life Sciences director Angermayer buys $2.52 million in shares By Investing.com - Investing.com UK
Atai Life Sciences director Angermayer buys $2.52 million in shares - Investing.com
Psychedelic: atai Life Sciences, NRx report quarterly results - Yahoo Finance
Atai Life Sciences N V (ATAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Atai Life Sciences N V 주식 (ATAI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Craig Kevin James | Chief Medical Officer |
Mar 21 '25 |
Sale |
1.35 |
11,563 |
15,610 |
8,437 |
| Rao Srinivas | See Remarks |
Mar 21 '25 |
Sale |
1.35 |
75,418 |
101,814 |
212,942 |
| Johnson Anne Nagengast | Chief Financial Officer |
Mar 21 '25 |
Sale |
1.35 |
33,545 |
45,286 |
140,045 |
| Short Glenn Frank | Chief Scientific Officer |
Mar 21 '25 |
Sale |
1.35 |
13,161 |
17,767 |
42,333 |
1.54%
7.58%
자본화:
|
볼륨(24시간):